

Seasonal influenza vaccination In Latin America and the Caribbean

Symposium on Seasonal Influenza Vaccination Policy Development and Implementation

Alba Maria Roperó-Alvarez
PAHO Immunization Regional Advisor

Beijing, 17-18 June, 2017

Outline

- Progress in influenza vaccination in the Americas
- Seasonal influenza vaccination in tropical countries in LAC
- PAHO Revolving Fund for vaccines
- Operational challenges

Milestones in the 40 years of the EPI in the Americas

1977


PAHO's
Directing
Council
establishes
the EPI

1977	PAHO's Directing Council establishes the EPI
1979	Creation of the Revolving Fund
1980	Creation of international evaluation methodology for the EPI
1983	"Days of Tranquility"
1985	Creation of the EPI Technical Advisory Group (TAG)
1985	Creation of the Interagency Cooperation Committee
1991	Last indigenous case of polio in Peru
1994	Declaration of the goal to eliminate measles
1994	1st Region certified free of polio
2003	1st Vaccination Week in the Americas
2006	Launch of the Pro-Vac initiative
2010	Directing Council resolution on strengthening the EPI (RIVS)
2012	1st World Immunization Week
2013	Directing Council resolution on the principles of the RF
2015	1st Region free of rubella
2015	Directing Council resolution on the Regional Imm Action Plan
2016	OPV Switch
2016	1st Region free of measles

2016

2017

Days of Tranquility




**El Salvador
(1985-1991)**

Multiple, three-day
truces negotiated

Campaigns repeated
three times a year for
immunization against
polio and other
diseases



PAHO's Regional Vaccination Program: Across the Life Cycle



PAHO's TAG Influenza Recommendations 2004-2015

All countries should strengthen their surveillance systems in order to determine:

- influenza disease burden
- cost-effectiveness of influenza vaccine introduction
- best vaccination strategy to use, formulation and when (especially in tropical countries)


All countries should establish a seasonal influenza vaccination policy that seeks to vaccinate:

- individuals with chronic illness, the elderly and pregnant women
- children 6-23 months of age
- health workers

Countries using the vaccine should generate coverage data and document experiences and lessons learned from targeting high-risk groups.

Introduction of influenza vaccines the Americas

No. countries with policies for seasonal flu vaccination




Countries and Territories in the Americas with Policies for seasonal influenza vaccination, 2004-2015

Number (%) of countries that have:	2004	2008	2015
Policies for influenza vaccination	13	35	40/45 (89%)
Vaccination of healthy children <i>(expansion of age range)</i>	6	22	25 (56%) 4
Vaccination of children with chronic diseases			5 (11%)
Vaccination of the elderly <i>(expansion of age range)</i>	12	33	39 (87%) 5
Vaccination of persons with chronic diseases	9	24	35 (78%)
Vaccination of health care workers	3	32	38 (84%)
Vaccination of pregnant women	3	7	31 (69%)

Source: Country Reports to PAHO (JRF), MOH web pages, PAHO/WHO Surveys

Data not collected from the French Departments (French Guiana, Guadeloupe, Martinique).

Countries with influenza vaccination policies




Data source: WHO/IVB Database, as of 29 September 2015
Map production Immunization Vaccines and Biologicals (IVB),
World Health Organization

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. ©WHO 2015. All rights reserved.



Influenza vaccine distribution by WHO Regions 2004-2013



AF = Africa, SEA = South East Asian, EM = Eastern Mediterranean,
WP = Western Pacific, EU = European, AM = Americas

Influenza vaccination strategies

Countries use combined vaccination strategies to reach high risk Groups:

- **Short**, intensive vaccination campaigns - Vaccination Week (SHF),
- Following up with **routine vaccination** through health services during the influenza season, or until until stocks exhaust or expire



QUEM LEMBRA DA VACINA SE PROTEGE DA GRIPE.

Gestantes	
Pessoas com 60 anos ou mais	Crianças de 6 meses a menores de 2 anos
Mulheres no período pós-parto	Portadores de doenças crônicas

DE 15 A 26 DE ABRIL. VACINAÇÃO CONTRA GRIPE.
PROCURE UM POSTO DE VACINAÇÃO E PROTEJA-SE.




Example of Influenza vaccination campaign in Brazil, 2016

Population	Target	% coverage
Children (6mo to <5yrs)	12.824.6818	66,47
Healthcare workers	4.081.346	86,50
Pregnant women*	2.232.160	56,63
Post-partum ≤ 45 days*	366.930	79,37
Elderly	20.889.849	72,92
Indigeneous Pop.	620.318	38,80
Total (include Others)	49.880.838	70,51



Seasonal influenza coverage in children 6-23 months in reporting countries. LAC, 2015-2016




Source: Country reports through the PAHO-WHO Joint Reporting Forms (JRF), 2016 and 2017; USA data 2015 (2014-2015 season) and 2016 data (2015-2016 season)

Note: Pediatric coverage formula: $((2\text{nd dose} + \text{single dose}) / \text{denominator}) * 100$

* Provisional data


Seasonal influenza coverage in >60 years in reporting countries. LAC, 2015-2016*



Source: Country reports through the PAHO-WHO Joint Reporting Forms (JRF), 2016 and 2017; USA data 2015 (2014-2015 season) and 2016 data (2015-2016 season)

* Provisional data


Seasonal influenza coverage in pregnant women in reporting countries. LAC, 2015-2016*



Source: Country reports through the PAHO-WHO Joint Reporting Forms (JRF), 2016 and 2017.

* Provisional data

Seasonal influenza coverage in healthcare workers in reporting countries. LAC, 2015-2016*




Source: Country reports through the PAHO-WHO Joint Reporting Forms (JRF), 2016 and 2017.

* Provisional data

Outline

- Progress in influenza vaccination in the Americas
- Seasonal influenza vaccination in tropical countries in LAC
- PAHO Revolving Fund for vaccines
- Operational challenges

Seasonality-Influenza peaks




*Summary of seasonality analysis by
CDC, NIVEL, PATH, WHO and published literature*

Influenza surveillance is key to guide vaccination policies

Data sources

- OMS-GISRS-FluNet
- SARI and ILI surveillance
- Research platforms across Central America
- REVELAC-i
- Strains characterization at WHO CC.
- Models for seasonality

when to vaccinate and
what formulation to use?




Inter-Institutional
work

Influenza circulation by sub-region, LAC 2012-2017

Influenza circulation by region. 2012-17


Circulación virus influenza por región. 2012-17



Influenza viruses/Virus influenza

- Influenza A(H3N2)
- Influenza A(H1N1)pdm09
- Influenza A Not Subtyped/No subtipificado
- Influenza B
- Influenza A not subtypeable/no subtipifica...
- % Influenza


Negative binomial model for influenza activity in the American Tropics



**Predominant antigenic characterization of
influenza strain compared with vaccine
formulation during 2002–2014.**


Country	Years of available data	Years predominant strain represented	
		Southern hemisphere vaccine	Northern hemisphere vaccine
Brazil	11	73%	55%
Costa Rica	8	50%	50%
El Salvador	9	56%	44%
Guatemala	7	71%	43%
Honduras	7	43%	43%
Nicaragua	7	57%	57%
Panama	9	44%	44%
Paraguay	9	89%	56%
Total	67	61%	49%

Use of seasonal influenza vaccine & formulation in the Americas, 2014



Source: Country reports to PAHO, MOHs Webpage, PAHO/WHO Surveys


Adjustment of Influenza vaccine policy in tropical countries in LAC, 2015




Source: Country reports to PAHO, MOHs Webpage, PAHO/WHO Surveys

TAG Recommendations for tropical areas, 2015

- Determine the period of **highest influenza activity** using various data sources and methods
- **Vaccinating** intensively prior to the primary peak, reaching high coverage, and follow-up through health services during the influenza season
- using the **most updated vaccine** available
- **Evaluate** the impact of the change in vaccine policy



Decision-making process to change to Southern Hem formulation in Honduras



Analysis for decision-making

Technical-political	Programmatic - feasibility
<ul style="list-style-type: none"> ✓ Disease burden studies and seasonality analysis 2008-2012 ✓ TAG/WHO Recomendatios ✓ Quality Vaccines available. ✓ Financial analysis: <ul style="list-style-type: none"> - Vaccine price at the Revolving Fund - National budget requested by 2015 	<ul style="list-style-type: none"> ✓ National Experience on introduction of new vaccines ✓ Cold chain capacity in all levels ✓ Logistic and operational components

Main activities

- **Technical and operational guidelines** for the **transition**
- **Vaccine purchase** to the Revolving Fund
- Bulletins to inform about the transition
- Meetings with key stakeholders: private **sector**, **medical associations** y **pharma companies**
- **Communication strategy**
- Integration of influenza vaccine to **VWA**

Outline

- Progress in influenza vaccination in the Americas
- Seasonal influenza vaccination in tropical countries in LAC
- PAHO Revolving Fund for vaccines
- Operational challenges

PAHO Member States and its Revolving Fund for Vaccines

- **1977 CD25.R27** “Establishment of the Expanded Program on Immunization (EPI) and the PAHO Revolving Fund”
- **2013 CD52R5** “Principles of the PAHO Revolving Fund for Vaccine Procurement”
- **2013 CD52/15** “Review of the Charge Assessed on the Procurement of Public Health Supplies for Member States”
- **2014 CD53/23 Report** “PAHO Revolving for vaccine procurement: Challenges and Opportunities”

Solidarity
working together



Active
participation

Regional Goals
eliminating diseases, introducing new vaccines



PAHO Revolving Fund:

“One Pillar in Success of Immunization Programs in the Americas”

1979

2017

PAHO
Revolving
Fund

1979:
37 years

46 vaccines



29

syringes and
cold chain products



31 providers



41

countries and territories
in Latin America and the Caribbean

Vaccination
coverage
in the Americas

93%

for diphtheria-
tetanus-
pertussis

Over

95%

of vaccine costs
covered with
national funds

15
million

people vaccinated
through the fund in 2013

\$620 MM


Procured in 2016

Working capital
of more than

\$162MM

In 2016 (for 60 days credit)


PAHO Revolving Fund: Procurement Cycle and Stakeholders



Influenza vaccine procurement through RF

Hemisferio Norte

20 países/territorios



Hemisferio Sur

13 países/territorios

ARG, BRA, CHI, MEX do not participate in the RF for Influenza vaccine procurement (Transfer technology agreements, public-private partnerships)

Seasonal Influenza Vaccination Operational Challenges

Estimating vaccination coverage:

- **Complexity** defining denominators for persons with chronic conditions and healthcare workers
- Difficult to record with the current information systems in many countries
- **Quality** of information systems:
 - Coverage rates for all targeted populations groups are not routinely available – absence of reliable denominators including pregnant women
 - Two-dose schedule for children <9y vaccinated for the first time
 - Electronic registries

Seasonal Influenza Vaccination

Operational challenges

Social communication strategies:



- Boost community confidence and generate demand to counter misinformation disseminated by anti-vaccine groups
- Opinion-makers and social communicators: appropriate information in order to provide extensive coverage on the vaccine's benefits - Champions
- Develop materials for different audiences
- Use of new technologies like social media to better disseminate information
- Communication campaigns must be timed adequately based on seasonality and vaccine availability

Source: PAHO

Communication skills for health care workers to support influenza vaccine uptake

Seasonal Influenza Vaccination

Operational challenges

Influenza vaccination in pregnant women:

- Generate **evidence** on influenza illnesses burden and vaccine effectiveness and impact among pregnant women and newborns
- Strengthen **AEFI surveillance** including active surveillance using sentinel sites
- Medical/scientific societies, physician vaccine **recommendations** are critical to achieve higher rates of vaccination
- Strengthen **collaborative efforts** among scientific societies/associations and NiTAGs, Agencies, Universities and Institutions working on MCH

Conclusions

- Progress in the generation of evidence for influenza adjustments to **vaccination policies in tropical countries** (surveillance, disease burden, vaccine performance, information systems and coverage monitoring-nominal registries)
- Countries still face **challenges to fully implement** influenza vaccination in target populations
- Quality of information systems
 - Coverage rates for all targeted populations groups are not routinely available – absence of reliable denominators including pregnant women
 - Two-dose schedule for children <9y vaccinated for the first time
- Need to continue the evaluation of vaccine effectiveness and impact

Acknowledgements

- Nathalie El Omeiri
- Jhon Fitzsimmons
- Daniel Rodriguez
- Carilu Pacis
- Ministries of Health